Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis

Human Reproduction

Volumn 24, Issue 5, 2009, Pages 1025-1035

  Novella Maestre, Edurne ^a   Carda, Carmen ^a   Noguera, Inmaculada ^a   Ruiz Saurí, Amparo ^a   García Velasco, Juan Antonio ^a   Simón, Carlos ^a   Pellicer, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiogenesis; Cabergoline; Dopamine agonists; Endometriosis; Vascular endothelial growth factor

Indexed keywords

CABERGOLINE; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED IMPLANTATION; DRUG EFFECT; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEUM; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE STRUCTURE; TREATMENT DURATION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 67449119296     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den499     Document Type: Article

References (44)

1. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simon C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92:2931-2937.
2. Basu S, Dasgupta PS. Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 1997:42:1260-1264.
3. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001 ;7:569-574.
4. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by Inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004:64:5551-5555.
5. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman J, D'Amato RJ. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005:84:1144-1155.
6. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and Is regulated by PDGF B and VEGF. Development 1998:125:1591- 1598.
7. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 2006; 132:501-519.
8. Buhendwa L, Zachariah R, Teck R, Massaquoi M, Kazima J, Firmenich P, Harries AD. Cabergoline for suppression of puerperal lactation in a prevention of mother to child HIV transmission programme in rural Malawi. Trop Doct 2008;38:30-32.
9. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Grillo S et al. Predictors of remission of hyperprolactlnaemia after long term withdrawal of cabergoline therapy. Clin Endocrinol 2007;67:426-433.
10. Cunha-Filho JS, Gross JL, Lemos NA, Dias EC, Vettori D, Souza CA, Passos EP. Prolactin and growth hormone secretion alter thyrotrophin-releaslng hormona Infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis. Hum Reprod 2002:17:960-965.
11. Donnez J, Smoes P, Gillerot S, Casanas Roux F, Nisolle M. Vascular endothelial growth factor in endometriosis. Hum Reprod 1998; 13:1686 1690.
12. Eggermont J, Donnez J, Casanas Roux F, Scholtes H, Van Langendonckt A. Time course of pelvic endometriotic lesion revascularization in a nude mouse model. Fertil Steril 2005;84:492-499.
13. Eljarmak D, Lis M, Cantin M, Carriere PD, Collu R. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res 1985;21:160-167.
14. Ferrara N. Role of vascular endothelial growth factor In physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29:10-14.
15. Galle PC. Clinical presentation and diagnosis of endometriosis. Clin North Am 1989:16:29-42.
16. Gargett C, Weston G, Rogers P. Mechanisms and regulation of endometrial angiogenesis. Reprod Med Rev 2002; 10:45-61.
17. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006:27:485-534.
18. Gómez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C, Pellicer A. Low dose dopamine agonist administration blocks VEGF mediated vascular permeability without altering VEGFR-2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-5411.
19. Gregoriou G, Bakas P, Vitoratos N, Papadias K, Goumas K, Chryssicopoulos A, Creatsas G. Evaluation of serum prolactin levels in patients with endometriosis and infertility. Gynecol Obstet Invest 1999; 48:48-51.
20. Hull ML, Charnock Jones DS, Chan CL, Bruner Tran KL, Osteen KG, Tom BD, Fan TP, Smith SK. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003; 88:2889-2899.
21. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007:13:331-342.
22. Maas JW, Groothuis PG, Dunselman GA, de Goeij AF, Struijker-Boudier HA, Evers JL. Development of endometriosis-like lesions after transplantation of human endometrial fragments onto the chick chorioallantoic membrane. Hum Reprod 2001 a;16:627-631.
23. Maas JW, Groothuis PG, Dunselman GA, de Goeij AF, Struijker Boudier HA, Evers JL Endometrial angiogenesis throughout the human menstrual cycle. Hum Reprod 200 Ib; 16:1557-1561.
24. Machado DE, Abrao MS, Berardo PT, Taklya CM, Nasciutti LE. Vascular density and distribution of endothelial growth factor (VEGF) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008:90:148-155.
25. Mahnke JL, Dawood MY, HuangJC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 2000:73:166-170.
26. McCarthy M. Angiogenesis drug promising for metastatic colorectal cancer. Lancet 2003:361:1959.
27. McLaren J, Prentice A, Charnock Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996a; 11:220-223.
28. McLaren J, Prentice A, Charnock Jones DS, Millican SA, Muller KH, Sharkey AM, Smith SK. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996b;98:482-489.
29. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL, Evers JL Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004:89:1089-1095.
30. Nisolle M, Casanas Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization In peritoneal endometriosis. Fertil Steril 1993:59:681-684.
31. Park A, Chang P, Ferin M, Xiao E, Zeltoun K. Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis. Fertil Steril 2004;82:S71.
32. Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med 1991;36:513-515.
33. Reese J, Binart N, Brown N, Ma WG, Paria BC, Das SK, Kelly PA, Dey SK. Implantation and decidualization defects in prolactin receptor (PRLR)-deficlent mice are mediated by ovarian but not uterine PRLR. Endocrinology 2000; 141:1872-1881.
34. Ricci E, Parazzini F, Motta T, Ferrari Cl, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002:16:791-793.
35. Robert E, Musatti L, Piscitelli G, Ferrari Cl. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10:333-337.
36. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927:14:422-469.
37. Schade R, Andershon S, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med 2007; 356:29-38.
38. Shalaby F, Rossant J, Yamaguchl TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood island formation and vasculogenesis in Flk I-deficient mice. Nature 1995:376:62 66.
39. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and In the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996:81:3112-3118.
40. Verhelst J, Abs R, Maiter D, Van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P et al. Cabergoline in the treatment of hyperprolactinemia: a study of 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
41. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000;5:45-50.
42. Via LE, Gore Langten RE, Pluda JM. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology 2000; 14: 1312-1323.
43. Watkins RH, D'Angio CT, Ryan RM, Patel A, Maniscalco WM. Differential expression of VEGF mRNA splice variants In newborn and adult hyperoxic lung injury. Am J Physiol 1999;276:858-867.
44. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.